清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review

作者
Mariacarmela Santarpía,Giuliana Ciappina,Calogera Claudia Spagnolo,Andrea Squeri,Maria Ilenia Passalacqua,Andrés Aguilar,María González‐Cao,Elisa Giovannetti,Nicola Silvestris,Rafael Rosell
出处
期刊:Translational lung cancer research [AME Publishing Company]
卷期号:12 (2): 346-368 被引量:72
标识
DOI:10.21037/tlcr-22-639
摘要

Background and Objective: Non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) driver alterations harbors a poor prognosis with standard therapies, including chemotherapy and/or immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) antibodies. Selective KRAS G12C inhibitors have been shown to provide significant clinical benefit in pretreated NSCLC patients with KRAS G12C mutation. Methods: In this review, we describe KRAS and the biology of KRAS-mutant tumors and review data from preclinical studies and clinical trials on KRAS-targeted therapies in NSCLC patients with KRAS G12C mutation. Key Content and Findings: KRAS is the most frequently mutated oncogene in human cancer. The G12C is the most common KRAS mutation found in NSCLC. Sotorasib is the first, selective KRAS G12C inhibitor to receive approval based on demonstration of significant clinical benefit and tolerable safety profile in previously treated, KRAS G12C-mutated NSCLC. Adagrasib, a highly selective covalent inhibitor of KRAS G12C, has also shown efficacy in pretreated patients and other novel KRAS inhibitors are being under evaluation in early-phase studies. Similarly to other oncogene-directed therapies, mechanisms of intrinsic and acquired resistance limiting the activity of these agents have been described. Conclusions: The discovery of selective KRAS G12C inhibitors has changed the therapeutic scenario of KRAS G12C-mutant NSCLC. Various studies testing KRAS inhibitors in different settings of disease, as single-agent or in combination with targeted agents for synthetic lethality and immunotherapy, are currently ongoing in this molecularly-defined subgroup of patients to further improve clinical outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
12秒前
平淡大船完成签到,获得积分10
17秒前
虚心晓灵完成签到,获得积分10
17秒前
tuimao发布了新的文献求助10
20秒前
Lucas的应助被tuimao采纳,获得10
28秒前
等风的拾荒者完成签到 ,获得积分10
30秒前
35秒前
AiQi完成签到 ,获得积分10
36秒前
伶俐的万言完成签到,获得积分10
50秒前
在水一方的应助被WQY采纳,获得10
50秒前
TingtingGZ发布了新的文献求助10
53秒前
58秒前
WQY发布了新的文献求助10
1分钟前
旧城旧巷等旧人完成签到 ,获得积分10
1分钟前
1分钟前
殷勤的鸵鸟完成签到,获得积分10
1分钟前
loen完成签到,获得积分10
1分钟前
杉寒完成签到,获得积分10
1分钟前
务实的绮琴完成签到,获得积分10
1分钟前
2分钟前
ramsey33完成签到 ,获得积分10
2分钟前
tuimao发布了新的文献求助10
2分钟前
Orange的应助被tuimao采纳,获得20
2分钟前
科研通AI6.2的应助被JJYYY采纳,获得10
2分钟前
tfonda完成签到 ,获得积分10
2分钟前
Tree_QD完成签到 ,获得积分10
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
QQQQQQ完成签到 ,获得积分10
2分钟前
大气翠风完成签到,获得积分10
2分钟前
syvshc的应助被WQY采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
柔弱的妙旋完成签到,获得积分10
3分钟前
和谐的山水完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767373
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697